Types of prostate cancer
Virtually all prostate
cancers are adenocarcinomas.
These cancers advance from the gland cells (the cells that create the prostate the fluid that is added to the semen).
Further types of prostate
cancer include:
•
Sarcomas
•
Small cell carcinomas
•
Neuroendocrine tumors
•
Transitional cell carcinomas
These other types of
prostate cancer are rare. If you have prostate cancer it is nearly definite to
be an adenocarcinoma.
The
prostate-specific antigen (PSA) biomarker
has been broadly used to screen men for prostate cancer. Examines of PSA
cancer-specific sensation and specificity occur; opportunely, a novel
generation of PCa biomarkers is developing, consisting of serum-, urine-, and
tissue-based assays that may supplement PSA testing, or exchange it over time
There are several reasons why
biomarkers are needed for prostate cancer, including
(i) For consistent
diagnosis of important prostate cancer and making therapy decisions
(ii) For an early estimate of prognosis of the upcoming course of the disease, which may lead to
adjusted monitoring and improved therapy
(iii) For calculation
of therapy response and thus stratifying potential treatment benefit
(iv) The identification
of another therapeutic target created on molecular analyses (eg. target
expression and mutational status);
(v) Emerging
individualized dealing options and thus recover patient outcomes
(vi) Standardization of
study/cohort design, authorizing identical reporting. The ideal biomarker would
be non-invasive/minimally invasive, have high accuracy and performance, and at
low cost.
Most important is
choosing the accurate biomarker at the correct time, whether a diagnostic or
prognostic biomarker. Some of the more commonly used biomarkers, 4Kscore, PCA3,
SelectMDx, ConfirmMDx, OncotypeDx, Prolaris and Decipher.
Check our Conference Session Biomarkers
J U L Y 15-16, 2019 | Abu Dhabi,
U A E
No comments:
Post a Comment